Healthcare provider profile · identity verified

Mary N Tilak, MD

Internal Medicine · MUNSTER, IN · NPI 1518054352

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Pantoprazole Sodium	Pantoprazole Sodium	202	80
Atorvastatin Calcium	Atorvastatin Calcium	196	85
Metoprolol Succinate	Metoprolol Succinate	169	68
Levothyroxine Sodium	Levothyroxine Sodium	162	59
Amlodipine Besylate	Amlodipine Besylate	129	57
Irbesartan	Irbesartan	108	39
Rosuvastatin Calcium	Rosuvastatin Calcium	99	43
Carvedilol	Carvedilol	85	32
Jardiance	Empagliflozin	85	28
Metoprolol Tartrate	Metoprolol Tartrate	76	26
Furosemide	Furosemide	74	27
Gabapentin	Gabapentin	72	36
Eliquis	Apixaban	70	25
Clopidogrel	Clopidogrel Bisulfate	69	32
Ozempic	Semaglutide	59	21
Losartan Potassium	Losartan Potassium	58	25
Spironolactone	Spironolactone	56	26
Repatha Sureclick	Evolocumab	53	14
Metformin Hcl	Metformin Hcl	51	24
Celecoxib	Celecoxib	49	16
Montelukast Sodium	Montelukast Sodium	49	17
Albuterol Sulfate Hfa	Albuterol Sulfate	46	24
Lisinopril	Lisinopril	45	23
Trazodone Hcl	Trazodone Hcl	44	13
Xarelto	Rivaroxaban	41	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	40	16
Doxazosin Mesylate	Doxazosin Mesylate	37	14
Fluticasone Propionate	Fluticasone Propionate	36	19
Synthroid	Levothyroxine Sodium	33	11
Omeprazole	Omeprazole	32	18
Tamsulosin Hcl	Tamsulosin Hcl	32	suppressed
Potassium Chloride	Potassium Chloride	30	11
Hydralazine Hcl	Hydralazine Hcl	28	11
Allopurinol	Allopurinol	27	11
Ezetimibe	Ezetimibe	27	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	27	18
Mounjaro	Tirzepatide	27	12
Duloxetine Hcl	Duloxetine Hcl	25	14
Simvastatin	Simvastatin	25	suppressed
Prednisone	Prednisone	24	21
Praluent Pen	Alirocumab	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Sertraline Hcl	Sertraline Hcl	22	12
Farxiga	Dapagliflozin Propanediol	21	suppressed
Entresto	Sacubitril/Valsartan	20	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	20	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Aripiprazole	Aripiprazole	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Glimepiride	Glimepiride	17	11
Linzess	Linaclotide	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Valsartan	Valsartan	16	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Torsemide	Torsemide	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Famotidine	Famotidine	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Risedronate Sodium	Risedronate Sodium	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error